414,845 Shares in DexCom, Inc. (NASDAQ:DXCM) Purchased by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 414,845 shares of the medical device company's stock, valued at approximately $32,262,000. Worldquant Millennium Advisors LLC owned about 0.11% of DexCom as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Private Trust Co. NA lifted its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. Optiver Holding B.V. bought a new position in shares of DexCom in the 4th quarter worth about $33,000. TD Private Client Wealth LLC lifted its stake in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC boosted its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in shares of DexCom during the 4th quarter valued at about $38,000. 97.75% of the stock is owned by institutional investors.

DexCom Stock Down 0.4%

Shares of NASDAQ DXCM traded down $0.32 during trading on Monday, hitting $84.51. The stock had a trading volume of 2,599,337 shares, compared to its average volume of 4,372,116. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $128.63. The firm has a fifty day moving average of $73.54 and a two-hundred day moving average of $78.26. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company has a market capitalization of $33.14 billion, a PE ratio of 59.10, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business's revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.32 earnings per share. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on DXCM shares. Barclays boosted their price target on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. Mizuho began coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Piper Sandler cut their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $98.00.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This trade represents a 10.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares in the company, valued at $10,002,636.06. This represents a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,926 shares of company stock valued at $4,734,384. Company insiders own 0.32% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.